Biocardia, Inc. annual report, FY2015

Business context and reporting period

Filing identity: The supplied filing is Tiger X Medical, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 25, 2016. It does not identify BioCardia, Inc.; the company and filing metadata therefore do not match. This is an annual report, not a standalone fourth-quarter report.

Tiger X had discontinued its former orthopedic device operations and sold substantially all related assets in 2011. Its continuing activity was collecting royalties from Arthrex, promoting former products, and evaluating a partner or buyer for remaining intellectual property and other investment opportunities. The company reported five remaining issued patents related to intervertebral stabilizers and no full-time employees other than its CEO/acting CFO, who received no salary.

Financial results and position

Amounts below are in thousands of dollars unless stated otherwise.

Operating margin was approximately 62% of royalty income in 2015, compared with 54% in 2014; net income was approximately 62% and 55% of royalty income, respectively. These ratios reflect the company’s limited royalty-based operations. The statements show no income tax provision. Reported basic and diluted earnings per share are displayed as “$-”; the filing text does not provide a clear per-share value.

At December 31, 2015, total assets were $13.876 million, including $13.840 million in cash and $36,000 in prepaid and other current assets. Total liabilities were $10,000, consisting of accounts payable and accrued expenses; no debt is reported. The filing states there were no investing or financing cash flows, contractual obligations, or off-balance-sheet financing arrangements. Management said cash was adequate for needs over the next twelve months and beyond.

Material changes versus 2014

• Royalty income increased by $90,000, which management attributed to higher Arthrex sales of the acquired product line.
• Operating cash flow increased to $331,000 from $214,000, primarily because of the higher royalty income.
• General and administrative costs were broadly stable. The company expected them to remain at a similar level.
• Cash increased by $331,000; no shares were issued, and shares outstanding remained 230,293,141 at year-end.

Outlook, risks, contingencies, and unusual items

• Revenue dependence: Until a partner, buyer, or investment opportunity is found, management expected royalties under the Arthrex agreement to remain the primary revenue source. The agreement provides royalties of 5% of qualifying net sales, payable quarterly for up to 20 years after closing.
• Royalty uncertainty: Collections depend on Arthrex sales and the company’s ability to verify and enforce payments. The agreement permits set-off for certain third-party intellectual-property claims and related costs.
• Cash concentration: Bank balances exceeded FDIC insurance limits by $13.593 million at year-end 2015. The company reported no prior losses from this exposure.
• Legal and product risks: The company retained potential product-liability exposure related to products sold before the asset sales. It maintained product-liability tail insurance, but warned coverage, retentions, and deductibles may be insufficient; it expects to be self-insured after the tail-insurance term. The company said it knew of no pending or threatened legal proceedings expected to have a material effect.
• Capital and governance risks: The filing cites possible difficulty obtaining future financing, potential dilution from equity issuance, limited trading liquidity and penny-stock restrictions, and significant insider ownership. Management reported no plans to pay cash dividends in the foreseeable future.
• Taxes: Deferred tax assets of $4.081 million were fully offset by a valuation allowance. Federal and state net operating loss carryforwards were approximately $10.425 million and $4.219 million, respectively, and may be subject to ownership-change limitations.
• Controls and audit: Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor issued an unqualified opinion on the financial statements but did not attest to internal-control effectiveness.

Most important facts for investors to verify

• Confirm that this Tiger X Medical filing—not a BioCardia filing—is the intended source.
• Review Arthrex royalty statements and agreement terms, including sales verification, set-off rights, and remaining payment term.
• Confirm the nature, accessibility, and bank distribution of the reported $13.840 million cash balance and the uninsured deposit exposure.
• Assess remaining product-liability tail coverage, deductibles, and potential exposure after coverage ends.
• Verify current ownership, share count, option dilution, and any subsequent corporate or investment developments; the filing describes a thinly traded OTC security.